IP Library Granted Patent US 10,792,378
Granted Patent B2
US 10,792,378 · App. 15/581,540 · Granted Oct 6, 2020

Using a blue-shifted reference dye in an optical glucose assay

Inventors: Soren Aasmul (Holte, DK); Jesper Svenning Kristensen (Virum, DK)
Assignee: Medtronics MiniMed, Inc.
A61K49/0056A61K49/0054C08B37/0021C08L5/02G01N33/542G01N33/66G01N2333/42G01N2400/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,792,378
App. No.
15/581,540
Granted
Oct 6, 2020
Kind
B2
Abstract

The invention is directed to a competitive glucose binding affinity assay comprising a glucose receptor (typically mannan binding lectin) labeled with an assay fluorophore and a modified glucose analog (typically dextran) labeled with a reference fluorophore. In certain embodiments, the glucose analog is dextran and is coupled to both a reference fluorophore and a quencher dye (e.g. hexamethoxy crystalviolet-1). Optionally the reference fluorophore is blue shifted relative to the assay fluorophore.

Claims (16)

1. A glucose sensing complex comprising:

a glucose binding agent coupled to an assay fluorophore; and

a glucose analog coupled to a reference fluorophore;

wherein:

the reference fluorophore is blue shifted relative to the assay fluorophore;

the assay fluorophore exhibits a wavelength that is at least 50 nanometers greater than the wavelength of the reference fluorophore; and

the assay fluorophore and reference fluorophore are individually selected from the group consisting of Alexa Fluor 594 (AF594), Alexa Fluor 647 (AF647), and Alexa Fluor 700 (AF700), and wherein the reference fluorophore has a lower wavelength than the assay fluorophore.

2. The glucose sensing complex of claim 1 wherein the glucose analog is further coupled to a quenching agent.

3. The glucose sensing complex of claim 2 wherein the quenching agent is hexamethoxy crystalviolet-1 (HMCV1).

4. The glucose sensing complex of claim 1 wherein:

the glucose binding agent is selected from the group consisting of mannan binding lectin (MBL), Concanavalin A, glucose galactose binding protein, an antibody, and Boronic acid; and/or

the glucose analog is dextran.

5. The glucose sensing complex of claim 4 wherein the glucose binding agent is mannan binding lectin.

6. The glucose sensing complex of claim 2 wherein the reference fluorophore and quencher dye form a Förster Resonance Energy Transfer (FRET) pair.

7. The glucose sensing complex of claim 2 wherein the fluorophores and/or quenching agent are water soluble.

8. The glucose sensing complex of claim 4 wherein the dextran is approximately 100 kDa.

Assignments (2)
SECURITY INTEREST Recorded Jan 16, 2026
From: MEDTRONIC MINIMED, INC.; COMPANION MEDICAL, INC.
To: CITIBANK, N.A.
Reel/Frame 074394/0237 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2017
From: AASMUL, SOREN; SVENNING KRISTENSEN, JESPER
To: MEDTRONIC MINIMED, INC.
Reel/Frame 043393/0473 →
Continuity (1)
Related Publication 20180311383A1 · Nov 1, 2018